ACETYL GLP1+GIP - Research Grade Peptide

ACETYL GLP-1 + GIP – Research-Grade Peptide Preparation

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Batch-defined acetylated GLP-1/GIP research peptide preparation
• Exact peptide identity, sequence, modification pattern and composition stated in the applicable completed Certificate of Analysis
• Supplied as measured dry or lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, molecular mass, peptide content and analytical specifications documented where supplied
• Restricted professional laboratory supply subject to customer, organisation and intended-use verification
• Handled and supplied exclusively as a research-use laboratory material

ACETYL GLP-1 + GIP is a catalogue designation for a batch-defined modified peptide preparation. The product name alone does not establish whether the supplied material is one sequence-defined peptide containing combined structural characteristics or a controlled mixture of two separate peptide components. The applicable batch Certificate of Analysis must identify which product format has been supplied.

Each vial contains measured laboratory material prepared to support controlled scientific handling, storage, analytical method development, chromatographic evaluation and mass-spectrometry characterisation. The stated nominal quantity refers to the declared peptide content of the vial according to the composition and assay basis stated in the applicable batch documentation.

Where laboratory dissolution is required, the solvent, buffer, concentration, mixing procedure, material-compatibility controls and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. A universal bacteriostatic-water instruction should not be applied to every peptide sequence, blend, salt form or modified peptide preparation.

Research Scientific Ltd does not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical, Structural and Composition Information:

• Catalogue Product Name: ACETYL GLP-1 + GIP
• Catalogue Product Identifier: PEP063
• Preferred Technical Description: Batch-defined acetylated GLP-1/GIP research peptide preparation
• Identity Status: The catalogue name alone does not define one unique molecular structure
• Required Product Classification: The completed batch documentation must identify PEP063 as either one sequence-defined modified peptide or a quantitative mixture of separately identified peptide components
• Single-Molecule Format: Where supplied as one molecule, the complete peptide sequence and every covalent modification must be stated
• Multi-Component Format: Where supplied as a mixture, each component must be listed separately with its complete sequence, modification pattern, molecular identity and quantity
• IUPAC or Sequence-Based Name: Batch-specific and not determinable from the commercial catalogue designation alone
• CAS Registry Number: No single CAS Registry Number should be assigned to the catalogue name without confirmation of the exact molecular identity; component-specific CAS numbers should be recorded where applicable
• Molecular Formula: Batch-specific and dependent upon the exact amino-acid sequence, terminal structures, acetylation, additional modifications and counter-ion form
• Mixture Formula Clarification: A two-component peptide mixture does not have one molecular formula; the formula of each component should be stated independently
• Molecular Weight: Batch-specific and dependent upon the exact molecular structure or component structures
• Mixture Molecular-Weight Clarification: A two-component mixture does not have one component molecular weight; the calculated and measured mass of each peptide should be recorded independently
• Complete Amino-Acid Sequence: Must be stated in the applicable completed Certificate of Analysis
• Component Sequences: Where supplied as a blend, the complete amino-acid sequence of every peptide component must be stated separately
• Acetylation Position: The residue or terminal group carrying the covalent acetyl modification must be identified
• Acetylation Stoichiometry: The number of covalently incorporated acetyl groups per peptide molecule must be stated
• Acetylation Clarification: Covalent acetylation must be distinguished from acetate acting as a salt-form counter-ion
• N-Terminal Structure: Batch-specific and to be stated in the applicable molecular-identity documentation
• C-Terminal Structure: Batch-specific; the free carboxylic acid or amidated form must be identified
• Additional Modified Residues: Any D-amino acids, 2-aminoisobutyric acid residues, non-proteinogenic residues or other substitutions must be declared
• Lipidation or Acylation: Any fatty-acid component, attachment site, linker and spacer structure must be stated where present
• Manufacturing Route: The material should only be described as synthetic, recombinant or semi-synthetic where that manufacturing route is supported by the supplier and batch-production records
• Recombinant-Status Clarification: The phrase “recombinant peptide analogue” should not be used unless recombinant expression and subsequent purification are documented
• Component Ratio: Required where the material contains more than one peptide component
• Individual Component Quantity: The nominal or measured quantity of each peptide component should be stated separately
• Total Nominal Vial Quantity: The product specification must state whether the declared vial amount represents total peptide content, one component, combined component content or total formulated material
• Physical Form: Dry powder or lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material where confirmed by the applicable batch documentation
• Chromatographic Purity: The applicable high-performance liquid chromatography result, method, detection wavelength and acceptance criterion should be stated for the defined molecule or separately for each component
• Purity Interpretation: Chromatographic area percentage is not automatically equivalent to net peptide content, molecular identity or component ratio
• Blend Quantification: A final chromatogram alone should not be used to infer component mass ratio unless the analytical method has validated response factors and suitable reference standards
• Mass-Spectrometry Identity: The measured mass should agree with the calculated mass of the defined peptide or with the individual calculated masses of every declared component
• Peptide-Content Assay: Net peptide content should be measured or calculated separately from chromatographic purity
• Component Assay: Where supplied as a blend, a validated quantitative method should confirm the amount or ratio of each peptide component
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify the free peptide, acetate-containing form, trifluoroacetate-containing form, sodium-containing form or other counter-ion presentation
• Counter-Ion Content: Acetate, trifluoroacetate, sodium or another counter-ion may affect total supplied material mass and calculated net peptide content
• Water-Content Specification: Residual water and hydration state may contribute to the total material mass and should be stated or controlled through the applicable batch specification
• Residual-Solvent Specification: Applicable residual solvents arising from synthesis, cleavage, modification, chromatographic purification, blending, concentration and lyophilisation should be stated or controlled through the batch specification
• Related-Impurity Control: Deletion sequences, truncated peptides, incompletely acetylated material, incorrect terminal forms, unmodified components and other synthesis-related or process-related substances are separate quality attributes
• Additional HPLC Purification: For a single-molecule ULTIMATE batch, the defined peptide undergoes the additional preparative purification stage; for a blend, each component should undergo the applicable additional purification before quantitative mixing
• Endotoxin Specification: The applicable bacterial endotoxin or lipopolysaccharide method, result, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Sterility Distinction: A bacterial endotoxin or lipopolysaccharide result does not establish sterility
• Dissolution Method: The appropriate solvent, buffer, concentration and mixing procedure should be selected using the exact sequence, composition, batch documentation and validated laboratory method
• Storage Specification: Storage conditions should be taken from the applicable stability data and completed batch documentation rather than assigned solely from the catalogue name
• Analytical Interpretation: Molecular identity, sequence, terminal structure, covalent modification, chromatographic purity, net peptide content, component ratio, counter-ion content, water content, residual solvents and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Completed batch documentation – The Certificate of Analysis should identify the exact single molecule or every component in the supplied preparation.
✓ Matching Safety Data Sheet – The Safety Data Sheet should use the same product identity, component description and chemical-form information as the applicable Certificate of Analysis.
✓ Sequence documentation – The complete amino-acid sequence or component sequences should be recorded.
✓ Modification documentation – Acetylation position, terminal structures, modified residues, linkers and lipid components should be declared where applicable.
✓ Component-ratio documentation – A multi-component preparation should state the individual quantity and quantitative ratio of each peptide.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the declared structure or structures.
✓ Chromatographic documentation – High-performance liquid chromatography purity should be reported separately from peptide-content assay and blend-ratio determination.
✓ Peptide-content documentation – Net peptide content should be distinguished from total vial mass, water, counter-ions and formulation components.
✓ Chemical-form documentation – Acetate, trifluoroacetate, sodium or other counter-ion presentations should be identified clearly.
✓ Endotoxin documentation – The bacterial endotoxin or lipopolysaccharide method, suitability controls, units, acceptance criterion and result should be recorded.
✓ Supplier documentation – Supporting synthesis or production, modification, purification, blending and analytical records should be reviewed where supplied.
✓ Trackable professional delivery – Securely packaged and dispatched using transport controls appropriate to the applicable batch stability and storage specification.

For Research Use Only
This product is supplied strictly for verified scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use, pharmacy compounding, self-administration or any form of therapeutic application.

ACETYL GLP-1 + GIP Product Overview

Our ACETYL GLP-1 + GIP research peptide preparation is supplied for controlled analytical method development, modified peptide identity assessment, high-performance liquid chromatography evaluation, liquid chromatography–mass spectrometry workflows, impurity profiling, quantitative composition assessment, reference-material comparison and other verified professional laboratory investigations.

The name ACETYL GLP-1 + GIP is a catalogue designation rather than a complete sequence-based chemical name. The applicable batch documentation must therefore establish whether the material consists of one sequence-defined modified peptide or a controlled preparation containing two separately characterised peptide components.

For a single sequence-defined molecule, the complete amino-acid sequence, stereochemistry, terminal structures, acetylation position, additional residue substitutions, linker, lipidation and calculated molecular mass should be recorded. For a two-component preparation, the same information should be provided separately for each peptide together with the individual component quantities and declared blend ratio.

No single CAS number, molecular formula or molecular weight should be assigned solely from the commercial product name. A multi-component preparation has component-specific molecular identities, while a single modified peptide requires its exact sequence and covalent structure before these identifiers can be established.

The material should be handled with a focus on batch traceability, documented molecular identity and consistent laboratory presentation. Product identity, complete sequence or component sequences, acetylation, terminal structures, chromatographic purity, net peptide content, component ratio, molecular form, counter-ion content, water content, residual solvents, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable completed batch Certificate of Analysis.

Chromatographic purity should not automatically be interpreted as equivalent to total net peptide content or quantitative blend composition. Different peptide components may produce different detector responses, so a chromatographic area ratio should only be treated as a mass ratio where the method has been validated for that purpose.

A bacterial endotoxin or lipopolysaccharide result does not establish sterility, complete molecular identity, correct acetylation, component ratio or the absence of every peptide-related and process-related impurity. Any sterility claim must be supported separately by an appropriate validated sterility test and controlled production documentation.

For the majority of routine analytical method development, chromatographic assessment, mass-spectrometry comparison, peptide characterisation, reference-material evaluation and general laboratory work, the Regular ACETYL GLP-1 + GIP specification remains highly suitable. The premium black-and-gold ULTIMATE option provides additional preparative high-performance liquid chromatography purification, enhanced identity and composition control, and a more stringent bacterial endotoxin or lipopolysaccharide testing specification for projects requiring enhanced quality-control parameters.

Supply is restricted to verified commercial, institutional and academic laboratory organisations. This catalogue listing must not be interpreted as offering an authorised medicinal product or a preparation intended for personal use.

View Certificate of Analysis

View Safety Data Sheet